Arecor Therapeutics plc (AIM:AREC)
70.00
+4.00 (6.06%)
May 26, 2026, 10:18 AM GMT
Arecor Therapeutics Revenue
In the year 2025, Arecor Therapeutics had annual revenue of 1.71M GBP with 4.32% growth.
Revenue
1.71M
Revenue Growth
-65.55%
P/S Ratio
14.54
Revenue / Employee
38.95K
Employees
44
Market Cap
24.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.71M | 71.00K | 4.32% |
| Dec 31, 2024 | 1.64M | -2.93M | -64.07% |
| Dec 31, 2023 | 4.57M | 2.17M | 90.30% |
| Dec 31, 2022 | 2.40M | 1.25M | 107.51% |
| Dec 31, 2021 | 1.16M | -540.00K | -31.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 4.64M |
| Fusion Antibodies | 1.60M |
| Aptamer Group | 1.38M |
| ImmuPharma | -69.96K |
Arecor Therapeutics News
- 4 weeks ago - Arecor Therapeutics Earnings Call Transcript: H2 2025 - Transcripts
- 4 weeks ago - Arecor Therapeutics Annual report: H2 2025 - Filings
- 4 weeks ago - Arecor Therapeutics Slides: H2 2025 - Filings
- 2 months ago - Arecor Therapeutics Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference - Transcripts
- 2 months ago - Arecor Therapeutics Slides: Investor presentation - Filings
- 8 months ago - Half Year 2025 Arecor Therapeutics PLC Earnings Presentation Transcript - GuruFocus
- 8 months ago - AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics - The Armchair Trader
- 8 months ago - Arecor Therapeutics Earnings Call Transcript: H1 2025 - Transcripts